Envestnet Asset Management
VVOS icon

Envestnet Asset Management’s Vivos Therapeutics VVOS Stock Holding History

Envestnet Asset Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,873
Closed -$111K – 4565
2025
Q1 		$111K Buy
+38,873
New +$153K ﹤0.01% 4225

Other funds holding VVOS

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Envestnet Asset Management's VVOS Position: Q2 2025 in Review

Envestnet Asset Management sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 38,873 shares — an estimated $111K sold.

Envestnet Asset Management first reported a position in VVOS in Q1 2025 and held it in 1 quarter. The position peaked at $111K in Q1 2025. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

  • Envestnet Asset Management reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 38,873 Vivos Therapeutics shares in Q2 2025, an estimated $111K.
  • Envestnet Asset Management first reported a position in Vivos Therapeutics in Q1 2025 and held it in 1 quarter.
  • Envestnet Asset Management's Vivos Therapeutics position peaked at $111K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.